Senolytics is a relatively new field of development that falls under the broad category of senotherapeutics, along with senomorphics and senostatics. Although nascent, the field could address the root causes of most chronic conditions brought on by aging as it clears senescent cells that have ceased to multiply (and ideally are eliminated from the body) but remain metabolically active after a senescence-associated secretory phenotype (SASP) change, which leads to disease conditions.
• What are the various drugs, modalities, development approaches, and technology advancements?
• Which growth opportunities can pave the way for the translation of senolytics to over-the-counter (OTC) treatments?
• Which innovations are likely to emerge in the next 5 years?
• What are the developments regarding mergers and acquisitions (M&As), partnerships, licensing, funding, and opportunity areas for growth?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
